This company listing is no longer active
Virtus Health Valuation
Is VRT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of VRT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: VRT (A$8.1) is trading above our estimate of fair value (A$5.32)
Muy por debajo del valor justo: VRT is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VRT?
Other financial metrics that can be useful for relative valuation.
What is VRT's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | AU$705.23m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.6x |
Enterprise Value/EBITDA | 13.1x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does VRT's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 38.2x | ||
MVF Monash IVF Group | 23.2x | 14.8% | AU$557.2m |
PSQ Pacific Smiles Group | 39.5x | 19.9% | AU$260.9m |
RHC Ramsay Health Care | 56x | 17.6% | AU$12.4b |
ACL Australian Clinical Labs | 33.9x | 24.4% | AU$523.3m |
VRT Virtus Health | 24.9x | n/a | AU$705.2m |
Price-To-Earnings vs. similares: VRT is good value based on its Price-To-Earnings Ratio (24.9x) compared to the peer average (75.3x).
Price to Earnings Ratio vs Industry
How does VRT's PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs. Industria: VRT is expensive based on its Price-To-Earnings Ratio (24.9x) compared to the Oceanic Healthcare industry average (24.6x)
Price to Earnings Ratio vs Fair Ratio
What is VRT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 24.9x |
Fair PE Ratio | n/a |
PM vs. Ratio Justo: Insufficient data to calculate VRT's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Insufficient data to show price forecast.